BriaCell to host conference call » 09:3706/1606/16/21
CEO Williams holds a…
CEO Williams holds a corporate and clinical update conference call on June 16 at 4:30 pm. Webcast Link
Atossa Therapeutics set to join Russell 2000, Russell 3000 Indexes » 09:0706/1606/16/21
Atossa Therapeutics announced it is set to be added to the Russell 2000 and Russell 3000 Indexes. This will take place at the conclusion of the 2021 Russell Indexes' annual reconstitution, effective after the U.S. market opens on June 28, 2021, according to a preliminary list of additions posted June 4, and June 14, 2021.
Fly Intel: Pre-market Movers » 08:5306/1606/16/21
SPI, KIN, ELAN, MNKD, ARVL, FORD, CNTG, ORCL, MX, BNTX, IKT, RBLX
Check out this morning's…
Bioceres collaborating with PlantArcBio to develop resistant alfalfa » 08:4506/1606/16/21
Bioceres announced a new…
Bioceres announced a new collaboration agreement with PlantArcBio, a gene discovery biotech company, for the development of improved biomass & drought tolerant Alfalfa, leveraging PlantArcBio's identified genes and Bioceres expertise in development of drought tolerant crops. In this collaboration, PlantArcBio has granted Bioceres the exclusive licensing rights to its biomass & drought resistance genes for Alfalfa worldwide; those genes were discovered by PlantArcBio. Bioceres will develop Alfalfa varieties incorporating those traits and will commercialize them. The agreement is contingent upon the successful incorporation of the genetic traits. Bioceres has developed a pipeline of alfalfa technologies currently at different stages of development, including drought tolerance, increased biomass and improved plant architecture. HB4 Alfalfa - drought tolerance - and different crop protection platforms are all entering regulatory stage. The global market for alfalfa hay is expected to grow at a CAGR of 5.89% to a market size of $20.6B in 2025, from $14.6B in 2019.
BriaCell expands breast cancer platform technology into other cancers » 08:2406/1606/16/21
BriaCell Therapeutics announces the advancement of its targeted oncology therapeutics into several novel immunotherapy cell lines: Bria-Pros for prostate cancer, Bria-Mel for melanoma, and Bria-Lung for lung cancer. BriaCell's immunotherapy treatment appeared most effective in breast cancer when the patient human leukocyte antigen molecules matched with the targeted immunotherapy, allowing BriaCell to potentially identify patients most likely to respond to the treatment. The novel approach uses an HLA-typing test - a simple and widely available test. BriaCell anticipates commencing clinical trials for these novel therapies in 2022. Bria-OTS in advanced breast cancer remains on track to commence patient dosing in 2021.
SPI Energy subsidiary launches EV charging solutions in U.S. » 07:1806/1606/16/21
SPI Energy announced its…
Story temporarily locked.
Aptinyx says finalized design of Phase 2b program for NYX-783 in PTSD patients » 16:1306/1506/15/21
The analyst says:…
The analyst says: "Aptinyx announced that it has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder, or PTSD, after having received the minutes from its recent Type C meeting with the U.S. Food and Drug Administration . The company expects to initiate the Phase 2b program in the fourth quarter of 2021. Aptinyx also announced that, in its preparation for Phase 2b, it identified a statistical error made by the contract research organization that performed the statistical analysis of the previously completed exploratory Phase 2 study in PTSD. Accordingly, the company is providing updated statistical analysis for the exploratory Phase 2 study, which has no impact on the study conclusions... In the process of completing its in-depth data analysis to prepare for and finalize the design of the Phase 2b program for NYX-783, the company identified a statistical modeling error made by the CRO that performed the statistical analysis of the previously completed exploratory Phase 2 study. The error resulted from an incorrect analysis of variance in the mixed model for repeated measures statistical model. While there were no changes to the numerical improvements from baseline, the revised MMRM p-values are higher than previously reported in October 2020. The CRO confirmed the error in late May and reported the updated statistical analysis to the company in June."
Largest borrow rate increases among liquid names » 08:4506/1406/14/21
ARVL, UPST, HTZGQ, IPOF, ATER, PRPO, CLII, SPI, LHDX, BNGO
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: Arrival (ARVL) 270.81% +107.38, Upstart Holdings (UPST) 83.44% +6.61, Hertz Global Holdings (HTZGQ) 20.53% +4.64, Social Capital Hedosophia VI (IPOF) 5.59% +3.93, Aterian (ATER) 14.66% +2.58, Precipio (PRPO) 37.93% +1.72, Climate Change Crisis Real Impact I Acquisition Corp (CLII) 16.84% +1.05, SPI Energy (SPI) 27.28% +0.41, Lucira Health (LHDX) 49.49% +0.39, and Bionano Genomics (BNGO) 1.96% +0.31.
Safehold increases quarterly stock dividend by 4.8% to 17c per share » 07:3606/1406/14/21
Safehold announced that…
Safehold announced that the Company's Board of Directors has declared common stock dividends of 17c per share for the second quarter of 2021. The dividend represents an annualized rate of 68c per share and is payable on July 15 to holders of record on June 30.
Atossa Therapeutics approved by Swedish MPA to start phase 2 study on endoxifen » 09:0506/1106/11/21
Atossa Therapeutics announces that it has received approval from the Swedish Medical Product Agency, or MPA, to initiate a Phase 2 clinical study of its oral Endoxifen for the reduction of mammographic breast density, or MBD. The primary objective of the MBD study is to determine the dose-response relationship of daily oral Endoxifen on mammographic breast density reduction, with secondary endpoints assessing safety and tolerability. The Phase 2 study will be randomized, double-blinded and placebo-controlled. It will include approximately 240 pre-menopausal women with measurable MBD who will receive daily doses of oral Endoxifen or placebo for six months.